The goal of this study is to examine a novel hypothesis that the progression of diabetes is partially due to the weakened survival of CD25 high T cells, and prolonging survival of CD25 high T cells inhibits the development of diabetes. Since CD28 co-stimulation is essential for the survival of CD4+CD25 high T cells, we determined whether CD28-upregulated translationally controlled tumor protein (TCTP) prolongs the survival of CD4+CD25 high regulatory T cells (Tregs) by a transgenic approach. The TCTP transgene prevents Tregs from undergoing apoptosis induced by interleukin-2 withdrawal-, dexamethasone-, cyclophosphamide-, and anti-Fas treatment in vitro. In addition, transgenic Tregs express higher levels of FOXP3 than wild-type counterparts and maintain suppressive activity, suggesting that TCTP promotes Tregs escape from thymic negative selection, and that prolonged survival does not attenuate Treg suppression. Moreover, TCTP transgenic Tregs inhibit the development of autoimmune diabetes due to increased survival of suppressive Tregs and decreased expression of pancreatic TNF-a.. Promoting the survival of CD25 high T cells leads to prolonged survival ofTregs but not activated CD25+ non-Treg T cells. Thus, we propose a new model of "two phase survival" for Tregs. Our results suggest that modulation of Treg survival can be developed as a new therapy for autoimmune diseases.
For improving Treg reduction in autoimmune diseases and developing Treg-based immune therapeutics (6) , a substantial quantity of wellsurvived suppressive Tregs would be needed. Therefore, three important questions remained to be answered: first, whether promotion ofCD25 high T cell survival leads to enhanced Treg survival or increased CD25+ non-Treg T cell survival; second, whether CD28 costimulation-and IL-2-signaled survival proteins play any critical roles in Treg apoptosis pathways; third, whether creation of Tregs that have prolonged survival inhibits diabetes. We established a CD25 high T cell-specific TCTP transgenic mouse model (TCTP Tg) and answered these questions.
MATERIALS AND METHODS

Electrophoretic gel mobility shift assay (EMSA)
Promoter sequence analyses were performed using the TRANSFAC (http://www.cbil.upenn.edu/cgi-bin/ tess/tess?RQ=SEA-FR-QueryS). EMSA was performed by using a Gelshift (activated T cell) kit (Active Motif, Carlsbad, CA). The bold fonts in IL-2 CD28RE and TCTP CD28RE sequences were the previously reported core of CD28RE (7) , and the underlined fonts were in the TCTP CD28RE mutant sequences ( Fig. 10 ).
Construction ofCD25 + T cell-targeting TCTP transgenic mice
The construction of the CD25+ T cell transgenic vector pCD25-TCTP-Tg was described previously (4) . Enforced expression ofTCTP in these transgenic mice was confirmed by Western blot with anti-FLAG antibodies (Sigma). All mice used in the experiments were age-and sex-matched. All animal experiments were 'approved by Temple University Institutional Animal Care and Use Committees.
Flow cytometric analysis
Lymphocytes were analyzed on FACSCalibur (BD Biosciences, San Jose, CA) after staining with FITC-, PE-, and PE-Cy7-conjugated monoclonal antibodies (mAbs) against: CD4, CD8a, GITR, CD3E, and CD25 (BD Pharmingen, San Diego, CA). PE-, PE-Cy7-and FITC-conjugated IgG were used as isotype controls (8) . Intracellular staining of Foxp3 was performed using a Treg staining kit (eBioscience, San Diego, CA) with anti-FOXP3 antibody (clone FJK-16s).
T Cell Purification
Tregs were purified from spleens and lymph nodes (LN) by mouse Tregs isolation kit (Miltenyi Biotec, Auburn, CA) (9) .
Suppressor Function Assay
Purified CD4+CD25-T cells were CFSE-labeled using the Cell Trace" CFSE Kit (Invitrogen). CFSE+CD4+CD25-T cells (1.5 x 10 5 ) were cultured with 10 5 autologous T cell-depleted splenic antigen-presenting cells (Dynabeads" Mouse Pan T -ThyI, 2, Invitrogen) in the presence of soluble anti-CD3E (l ug/ml), Various numbers (5 x 104, 2.5 x 104, 1.25 X 10 4 and 0.625 x 10 4 ) ofTregs were added to the cultures. Three days later, the cells were analyzed by FACS (9) .
Western Blot
The following antibodies were purchased from companies: anti-TCTP antibodies from BD PharMingen; anti-FLAG tag antibodies from Sigma; anti-If-actin and Bel-xL antibodies from Santa Cruz Biotechnology (Santa Cruz, CA); anti-mouse/rat FOXP3 antibody from eBioscience; and anti-mouse TNF-a antibodies from the R&D Systems (Minneapolis, MN). PI-3 kinase inhibitor LY294002 and Akt kinase inhibitor Wortmannin were purchased from Cayman Chemical (Ann Arbor, Michigan) and Millipore-Upstate (Billerica, MA), respectively.
T Cell Apoptosis Assay and IL-2 Withdraw Assay
Splenocytes were cultured in complete RPMI-1640 with 10% fetal calf serum (l0) alone, 10 nM dexamethesone, anti-Fas Ab 100 ng/ml (clone J02) (BD PharMingen) or 1 mM cyclophosphamide (Sigma), respectively. For IL-2 deprivation, cells (l x 10 6 ) were incubated with indicated concentrations ofIL-2. After 24 hours, the cell were collected and stained by PE-conjugated CD25 and PE-Cy7-conjugated CD4. The apoptosis rates were measured by flow cytometry using Annexin V-FITC Apoptosis Detection Kit II (BD Pharmingen).
RNA Analysis
RNA preparation and RT-PCR analysis were performed as reported (10) .
STZ-induced Autoimmune Diabetes
Tg and wild-type (WT) male mice (age 4 wk) received i.p. injections of40 mg/kg STZ (Sigma-Aldrich) dissolved in sodium citrate buffer (vehicle control) for 5 consecutive days. Non-fasting blood was obtained from the tail via a capillary tube and used for glucose level determination using ONETOUCH Ultra test Strips (LifeScan, Inc., Milpitas, CA). Mice were diagnosed as diabetic if nonfasting glucose levels were >"250 mg/dl(ll).
Histology
Pancreases were frozen in liquid nitrogen. Serial cryostatic sections (5 J.1m thick) were prepared for each pancreas. Hematoxylin-eosin (H&E)-staining and immunocytochemical experiments were used to study the presence of insulitis. Briefly, the acetone-fixed sections were subsequently stained with anti-FOXP3 mAb (BD PharMingen) overnight. After 3 washes with PBS-O.I% Tween 20, 4' ,6-diamidino-2-phenylindole (DAPI, Sigma), anti-rat/mouse Ig secondary antibodies conjugated with Texas Red (BD PharMingen) were applied (5) . Photographs were taken by Zeiss Axiovert 200 microscopy (Zeiss, Oberkochen, Germany).
RESULTS
TCTp, an anti-apoptotic protein, is temporally coupregulated with FOXP3 in T cells activated by TCR ligation and CD28 co-stimulation
We first asked whether TCR ligation with anti-CD3 antibody and CD28 co-stimulation with anti-CD28 antibody could enhance the upregulation of TCTP in T cells (5) . TCR ligation plus CD28 co-stimulation upregulated TCTP expression ( Fig.  lA) . In addition, the scale of TCTP upregulation (Fig. IB, blot 2) was higher than that of Bcl-xL (Fig. IB, blot I) in the same conditions, suggesting that the functional requirement for TCTP in supporting T cell survival and proliferation could be higher than that of Bcl-xL during T cell activation. Furthermore, the Treg-specific transcription factor FOXP3 was also co-upregulated with TCTP in mouse splenic T cells ( Fig. lB, blot 3) (3), suggesting that FOXP3 expression is upregulated in activated T cells, similar to that of CD25. Since CD28-/-deficient mice have only 20% of Tregs compared to wild-type controls (2), the results suggested that CD28 promoted survival signaling contributes significantly to Treg survival. Since it has been reported that CD28 co-stimulation signals through the PI3-Akt kinase pathway to promote T cell survival (12) , we then asked whether TCTP upregulation by TCR ligation and CD28 co-stimulation is also mediated via PI3 kinase pathway. The results showed that the TCTP upregulation in activated T cells was significantly inhibited by PI3 kinase inhibitor LY294002 ( . The results suggest that TCTP upregulation by CD28-co-stimulation requires the function of the PI3-Akt kinase pathway, which correlates with a previous report that PI3K signaling is critical for Treg survival (13) . Taken together, these results suggest that TCTP may play an important role in a Treg survival promoted by CD28 co-stimulation signaling.
It was then determined whether TCTP upregulation by TCR ligation and CD28 costimulation was mediated by a promoter-dependent transcriptional mechanism. We reported that TCTP upregulation in activated T cells is temporally associated with upregulation of interleukin-2 (IL-2) secretion from activated T cells (5) , suggesting that regulation of TCTP expression may be mediated by a signaling pathway similar to that regulating IL-2 expression. We thus examined the possibility of whether there is a cis-acting element in the TCTP promoter that may respond to CD28 co-stimulation. Our analyses of the TCTP promoter by searching the TRANSFAC database showed that a unique CD28 responsive element (CD28RE, a NF-KB like cis-acting element) (7) was located in the base pair (bp)~1747 of mouse TCTP promoter upstream of the transcription starting site. CD28 co-stimulation specifically targets the binding of CD28RE binding complex to CD28RE in IL-2 promoter, leading to a complete activation of the IL-2 promoter (12) . The results of EMSA showed that a double-strand fragment of TCTP CD28 RE, similar to IL-2 CD28RE control ( 
E) A working hypothesis ofTCTP upregulation in T cells activated by TCR ligation and CD28 costimulation presumably via a CD28RE:facilitated transcription mechanism.
of CD28RE in TCTP promoter suggest that TCTP is a survival protein in CD28 survival pathway. Of note, our extensive search did not find the CD28RE sequences in the promoter regions of other related survival proteins including BcI-2, BcI-xL, Mel-I and A I (5) . Tregs have higher susceptibility to apoptosis (6) , implying that expression of survival genes may be restricted to lower levels than those in CD4+CD25-T cells. Based on these results, we hypothesized that CD28 co-stimulation may promote Treg survival by upregulation ofTCTP (Fig. I E) .
TCT? transgene promotes the survival and positive selection ofCD4+CD25+FOXP3+ thymocytes
Two positive transgenic mouse strains were identified by mouse tail genomic DNA PCR using an mRNA-sense primer specific for the FLAG expression tag and an anti-sense primer specific for the TCTP sequence ( Fig. 2A, B , lines I and 2). The RT-PCR analysis on cDNAs prepared from CD25-TCTP transgenic tissues and control mouse tissues using a sense primer specific for FLAG expression tag and an antisense TCTP primer showed that Non -l ymp hoid
S-NIln .~~~:I:===::J """ " the TCTP transgenic transcripts were specifically expressed in lymphoid tissues including thymus, lymph nodes and spleen, but not in non-lymphoid tissues, such as liver and kidney nor in the lymphoid tissues from non-transgenic control littermates (Fig. 2C ). The control PCR with RNA preparations without reverse transcription oflymphoid tissues and non-lymphoid tissues from CD25-TCTP transgenic mice did not yield specific amplification (not shown). These results suggest that (i) TCTP transgenic cDNA amplifications in lymphoid tissues did not result from genomic DNA contamination, and (ii) TCTP transgenic mRNA transcripts were expressed in CD25 promoter-specific manner. In addition, the Western blot using anti-3xFLAG tag antibodies confirmed that TCTP transgenic protein was expressed in lymphoid tissues, such as thymus, lymph nodes and spleen, of CD25-TCTP transgenic mice but not in non-lymphoid tissues like liver and kidney ( Fig.  2D , blot I), nor in the lymphoid tissues and nonlymphoid tissues from wild-type control mice ( Fig.  2D , blot 2). In contrast, l3-actin as loading control was detected in every tissue examined ( Fig. 2D , blots 3 and 4), suggesting that the absence ofCD25-TCTP transcripts or protein in non-lymphoid tissues was due to the specific down-regulation of CD25 promoter. Furthermore, the semi-quantitative RT-PCR results presented in Fig. 2E showed that TCTP transcript expression in transgenic CD4+CD25+ T cells was increased at least by 3.1 fold in comparison to that in wild-type CD4+CD25+ T cells. The results from line I (Fig. 2C, D and E) were verified in the transgenic mice line 2. Collectively, these results showed that CD25-TCTP transgenic protein was expressed in the transgenic mice . We examined whether the development of major subsets of thymocytes was affected by TCTP transgene. The FACS analysis showed, in Fig. 3A , that the absolute cell numbers of major thymocyte subsets including CD4+ single positive, CD8+ single positive, CD4+CD8+ double positive, and CD4-CD8-double negative in TCTP transgenic mice were not statistically different from that of wild-type littermate controls (p>0.05). In addition, the percentages of major T cell subsets including CD4+, CD8+ and CD4+CD8+ in peripheral splenocytes and lymphocytes in lymph nodes (LN) in TCTP transgenic mice were not significantly changed in comparison to that in wild-type (WT) control mice (p>0.05). These results suggest that the homeostasis of major T cell compartments is independent from a prolonged survival of Tregs. As shown in Fig. 3B-2 , TCTP overexpression resulted in an elevated percentage (27.0%) of CD4+CD25+CD3 high thymocytes in the CD4+ single positive fraction compared with 21.1% in the subset in control mice. Since GITR is another Tregs marker (6), we also examined the GITR+ fraction of CD4+CD25+ thymocytes and peripheral CD4+CD25+ T cells. The results showed increased percentage of CD4+CD25+GITR+ thymocytes from 20.4% in wild-type controls to 25.4% in TCTP transgenic mice. In correlation with this finding, we also found that CD4+CD25+GITR+ Tregs fraction in lymph nodes was significantly increased from 44.6% in wild-type controls to 63.6% in TCTP transgenic mice ( Fig. 3B-3 , lower panel). In addition, since FOXP3 expression is a Treg specific transcription factor (6), we found that the percentage ofCD4+CD25 highFOXP3+ thymocytes was increased from 76.3% in wild-type controls to 84.0% in TCTP transgenic mice ( Fig. 3C-2, top left panel) . The percentage of CD4+CD25 highFOXP3+ splenic Tregs was significantly increased from 61.1% in wild-type controls to 89.9% in TCTP transgenic mice ( 
Fig. 4. TCTP transgenic Treg resistance to apoptosis. A) Resistance of TCTP transgenic Tregs to apoptosis. Splenocytes from wild-type control mice (black line) and TCTP transgenic mice (grey line) were incubated in the presence of 0 ng/ml, l ng/ml, 5 ng/ml and 20 ng/ml of IL-2for 24 hours followed by FACSanalysis ofapoptotic CD4+CD25high Tregs with FlTC-Annexin V. The experiments were repeated three times. B) FACS analysis of resistance of TCTP transgenic Tregs and wild-type control Tregs to apoptosis induced by Dexamethasone (Dex) and cyclophosphamide in the absence or presence ofIL-2. C) FACSanalysis ofresistanceofCD4+CD25high
Tregsfrom wild-type control mice and TCTP transgenic mice to apoptosis induced by anti-Fas antibody in the presence ofIL-2 ( Fig. 5 
. In vitro assay for Treg suppressive function. In vitro suppression of CD4+CD25-T cell proliferation (as judged by CFSE fluorescence dilution) by no Treg control (left panel), wild-type Tregs (middle panel) and TCT? transgenic Tregs (right panel). Thefluorescence intensity ofCFSE-labeled CD4+CD25-Tcells was decreased to 50% in eve,y cell division. The Treg suppressive function was measured by the percentage (%) of CFSE-Iabeled cell fractions in higher fluorescence intensities in the absence ofTregs (CD4+CD25-T cell proliferation control, left panel) and in the presence of Tregsfrom wild-type control mice (middle panel) and TCT? transgenic mice (right panel). "E" indicates the effector T cells, and "T" shows "Tregs".
The experiments were repeated three times.
percentage of splenic FOXP3+ cells, the expression levels of FOXP3 in splenic CD4+CD25 high T cells
as judged by the mean fluorescence intensity (MFI) were higher in TCTP transgenic mice than that in wild-type controls (not shown). Of note, the percentage of CD4+CD25 highFOXP3+ Tregs in lymph nodes (91.1%) of TCTP transgenic mice was not significantly higher than that (91.6%) in wild-type control mice ( Fig. 3C-4 , top right panel). Moreover, we found that the increased percentages of FOXP3+ were mostly residing in the CD4+CD25 high fraction of thymocytes and splenocytes in TCTP transgenic mice in comparison to that in wild-type controls, except that CD4+CD25 1owFOXP3+ Tregs were also increased in splenocytes ( Fig. 3C-3 , middle panel). The results further demonstrated that TCTP overexpression resulted in increased FOXP3+ Tregs. Ofnote, these results were verified in mice from both TCTP transgenic lines (not shown), suggesting that phenotyping changes resulted from TCTP transgenic protein function. These results suggest that TCTP transgene promotes the survival and positive selection of CD4+CD25+FOXP3+ thymocytes (14) , and that CD28 co-stimulation promotes the generation of CD4+CD25+FOXP3+ thymocytes at least partially via the function of anti-apoptotic protein TCTP.
TCTP transgene inhibited apoptosis of CD4+CD25 high T cells
Tregs are poor IL-2 producers (15) . Since sharing the CD28RE transcription mechanism with IL-2, TCTP may also be expressed in Tregs in low levels, which may be responsible for higher susceptibility of Tregs to apoptosis. The results presented in the left two lanes in Fig. 2E (CD4+CD25-T cells and CD4+CD25+ T cells from wild-type mice) supported this analysis. TCTP transgene promotes the survival and positive selection of CD4+CD25+FOXP3+ thymocytes. In addition, the percentage of CD4+CD25 highFOXP3+ splenic Tregs was significantly increased from 61.1% in wild-type controls to 89.9% in TCTP transgenic mice. Moreover, the results, in Fig. 4A , showed that transgenic TCTP inhibited apoptosis of CD4+CD25 high Tregs induced by IL-2 withdrawal (IL-2, 0 ng/ml) from 18.7% in wild-type controls to 12.7% in TCTP transgenic mice. When IL-2 supply was increased from 0 ng/ml to 20 ng/ml, the differences in apoptotic cell percentages between the TCTP Tregs and wild-type Tregs were decreased gradually, suggesting that at least in the IL-2 concentration range of 0 ng/ml to 10 ng/ml of IL-2 (Fig. 4A) , TCTP transgene replaced IL-2mediated Treg survival signal. Furthermore, the results showed that, in Fig. 4B , CD4+CD25+ Tregs were more susceptible to apoptosis induced by IL-2 withdrawal plus dexamethasone treatment, in which TCTP transgenic protein inhibited Treg apoptosis from 43.7% in wild-type mice to 36.4% in TCTP transgene (p<0.05). Similarly, transgenic TCTP reduced Treg apoptosis induced by cytotoxic drug cyclophosphamide from 27.6% in wild-type controls to 20.6% in TCTP transgenic Tregs (Fig. 4B ) 
lymphocyte infiltrates per islet (CI) , FOXP3+ cells per islet (Cl), and average numbers ofislets in each pan creas section (C3). D) Western blot analysis of TNF-C1. expression stimulated hy STZ in TCTP Tg pancreas and in wild-type pancreas. E) A working model in which Tregs with prolonged survival inhihit development ofS1Z-induced autoimmune
diabetes. Wild-type Tregs with higher susceptibility to apoptosis presumably could not cope with the lowered striking threshold of S1Z-induced autoimmune diabetogenic T cell clones . Tregs from TCTP transgenic mice with improved survival can improve the balance between Tregs versus effector T cells and inhibit the development of S1Z-induced autoimmune diabetes, presumably via elevating the striking thresholdfor diabetogenic T cell clones . In the right panel, the letters "T", "D ", "I " and "M" indicate the putative T cell clones mediating autoimmune diseases, such as thyroiditis, diabetes , inflammatory bowel disease, and myositis, respectively. Fig. 7 . A working model of two phase Tregs survival. In the first phase, CD28-promoted survival signal plays a dominant role for FOXP3+Tregs to "escape" the negative selection of thymocytes even TCRs on Tregs have high affinity for self-peptide/MHC complex expressed at thymic epithelial cells. In the second phase, IL-2/IL-2R signal plays a decisive role in Treg survival in the periphery. The data suggest that TCTP plays an important role in both phases ofTreg survival.
(p<0.05). The results suggest that TCTP transgene confers more resistance ofTregs to apoptosis induced by dexamethasone and cyclophosphamide. Finally, in Fig. 4C , the results show that TCTP transgene inhibited Treg apoptosis induced by anti-Fas antibody from 14.2% in WT control Tregs to 4.5% in TCTP Tg Tregs in the presence of IL-2 at 5ngl m1 (p<0.05). It was reported that Tregs are highly susceptible to CD95 ligand-mediated apoptosis (6) . Our results suggest that TCTP also inhibits death receptor Fas-initiated apoptosis.
Transgenic TCTP delayed the onset ofSTZ-induced diabetes
To further examine Treg suppressive function from TCTP transgenic mice, a T cell-dependent model of autoimmune diabetes (16) (17) induced by multiple low dose of STZ was adopted. Of
CD4+CD25 high regulatory T cells from TCTP Tg mice maintained their suppressive function
An important issue remained to be addressed: whether Treg suppressive function is coupled to their higher apoptotic status. In other words, whether Tregs that have a prolonged survival maintain their suppressive function. TCTP Treg transgenic mice provide a unique experimental system to examine this issue. In the previous section ( Fig. 3C-2, top center panel) , we demonstrated that CD4+CD25 highFOXP3+ splenic Tregs in TCTP transgenic mice were increased (1.47 fold) from 61.1% in wild-type controls to 89.9%, suggesting the maintenance of suppressive function of TCTP transgenic Tregs. Thus, next question was whether survived Tregs in TCTP transgenic mice really retain their suppressive function in addition to FOXP3 expression. CFSE-labeled CD4+CD25-T cell proliferation was used as a read-out assay for examining Treg suppression. Purified CD4+CD25 high T cells had 93.8% CD25+ phenotype (not shown), suggesting that the purification procedure was successful. After co-incubation ofTregs with CFSElabeled CD4+CD25-T cells in a ratio of 1:1, the no-proliferation cell percentage with the highest fluorescence ofCFSE was increased from 54% ( Fig.  5 , left panel) in no-Treg control group to 79.0% in wild-type Tregs control group (Fig. 5 , middle panel), suggesting that CFSE-labeled CD4+CD25-T cell proliferation was suppressed by wild-type Tregs. Similarly, in the same conditions, Tregs from TCTP transgenic mice also made the no-proliferation cell percentage with the highest fluorescence of CFSE, and were increased from 54% in the non-Treg control group to 79.8% (Fig. 5, right panel) , suggesting that TCTP Tregs are suppressive. Taken together, the results suggest that Tregs in TCTP transgenic mice with a prolonged survival retain their higher FOXP3 expression and suppressive function. su rv iva l note, Treg suppression depends not only on cell-cell contact but also on the function of suppressive cytokines TGF-~and IL-I0 (6) . A recent report showed that protection of animals from development of STZ-induced diabetes by anti-CD3 is TGF-~-dependent (17) , suggesting a possibility that Tregs may suppress STZ-induced autoimmune diabetes. Thus, we asked whether Tregs that have a prolonged survival in TCTP transgenic mice could inhibit the development of STZ-induced diabetes more efficiently. As shown in Fig. 6A , the incidence of STZ-induced diabetes was decreased from 45% in wild-type control group to 22% in the TCTP transgenic mouse group at day 12 after the first dose of STZ injection, and was decreased from 63% in wild-type controls to 43% in TCTP transgenic mice at day 21. By histological examination of pancreas tissue with H&E staining (Fig. 6B , upper panel), we found that STZ injections caused less infiltration of inflammatory cells (85 cells/islet) in TCTP transgenic pancreas in comparison to that of wild-type controls (133 cells/islet) ( Fig.  6C-l) . In addition, the results (Fig. 6B , lower panel) show that (a) FOXP3 staining was colocalized with DAPI (a nuclear DNA fluorescence dye), which correlated with reported sub-cellular location of transcription factor FOXP3; (b) more FOXP3+ positive cells were seen in the~-islet areas from TCTP transgenic mice (4.5 cells/islet) than that in wild-type pancreas controls (1.5 cells/ islet). Moreover, STZ decreased the average islet number per section from 7.5 in wild-type vehicle control to 3.8 in STZ-treated wild-type controls (p<O.OI) (Fig. 6C-3 ), suggesting STZ-induced islet destruction. In contrast, TCTP transgenic mice protected pancreas islets from STZ-induced immune destruction, as judged by increasing islet numbers from 3.8 islets/section in STZtreated wild-type controls to 6 islets/section in STZ-treated TCTP transgenic mice ( Fig. 6C-3 ) (p<O.05). Finally, since proinflammatory cytokine tumor necrosis factor-a (TNF-a) was found to be upregulated in STZ induced autoimmune diabetes ( 18) , we further examined the issue whether Tregs in TCTP transgenic mice inhibit upregulation of TNF-a in the inflamed pancreas induced by STZ. STZ treatment significantly induced TNF-a upregulation in pancreas (Fig.  6D ), which was inhibited in STZ-treated TCTP transgenic pancreas. Taken together, the results were summarized by proposing a new working model, as shown in Fig. 6E . STZ-treatment induces autoimmune diabetes, in which wildtype Tregs with higher susceptibility to apoptosis could not suppress diabetogenic T cell clones. In contrast, TCTP transgene improves the survival of Tregs while maintaining their suppressive function, which presumably raises the striking threshold of diabetogenic T cell clones and inhibits development of diabetes more efficiently.
DISCUSSION
Genetic analysis oftype I diabetes showed that IL-2 (Idd3) is among the several gene loci that determine the susceptibility to the disease (19) , suggesting that Treg survival affected by insufficientIL-2 supply may contribute to development ofautoimmune diabetes. Our current study demonstrates for the first time the following findings: (a) CD25 high Tregs have higher susceptibility to apoptosis than CD25+ non-Treg T cells, since promotion of CD25 promoter-survival protein TCTP Tg results in increased Treg survival more than CD25+ non-Treg T cell survival; (b) CD28 promotion of Treg survival is contributed via TCTP upregulation; (c) transgenic TCTP can replace IL-2 survival signal, and inhibit Treg apoptosis induced by IL-2 withdrawal, chemotherapy drugs dexamethasone and cyclophosphamide, and death receptor Fas ligation; (d) Tregs in TCTP transgenic mice maintain their high expression levels of FOXP3 and suppressive function. In contrast to the loss of Treg suppressive activity in the presence of anti-GITR and anti-OX40 agonist antibodies, it was found that increased Treg survival is not coupled with loss of Treg suppression; (e) promotion of Treg survival by TCTP Tg significantly inhibits the progression of STZ-induced autoimmune diabetes. Therefore, the results proved the principle that Treg-specific apoptotic pathways can be targeted for therapeutic intervention of autoimmune diabetes; and Tregs having a prolonged survival are still suppressive, which make production of a large number of suppressive Tregs for Tregs-based therapy feasible.
Identification of CD28RE in TCTP promoter suggests that expression of TCTP upregulated by CD28 co-stimulation was transcription-mediated, suggesting that definition ofTCTP role in regulating CD25 high T cell survival by transgenic approach was justified. Previous studies showed that the CD25 promoter is capable of targeting the transgenic reporter gene in T cells with a CD25-specific expression pattern (20) . Up to 96% ofCD4+CD25 high Tregs express FOXP3 (21) , suggesting that CD25 high is an essential marker for FOXP3+ Tregs (22) (23) . In addition, the transgenic TCTP promotes more survival of CD25 highFOXP3+ Tregs than that of CD4+CD25+intennediate, proving the suitability of CD25 promoter. Of note, FOXP3 per se promotes Treg apoptosis (24) , and FOXP3 expression in activated T cells leads to not necessarily acquisition of suppression function (25) . In order to determine whether CD25 high Tregs have higher susceptibility to apoptosis than CD25+ non-Treg T cells, we used CD25 promoter for this study, whereas FOXP3 promoter may not be suitable for this purpose.
In addition, the following evidence suggests that adoption of STZ-induced diabetes model in this study is appropriate: Firstly, multiple low dose of STZ-induced diabetes is a well-characterized T cell-mediated autoimmune diabetes (16) (17) 26) ; secondly, the susceptibility genes of mice to STZinduced diabetes are mapped to the same gene loci that are responsible for development of spontaneous diabetes in NOD mice (27) , suggesting the similarity of autoimmune mechanism in contributing to the development of diabetes in both models; thirdly, the potential role of Tregs in suppression of STZinduced diabetes has been reported (11).
These results further suggest that TCTP inhibits death-receptor Fas-mediated apoptosis, presumably due to the fact that TCTP inhibits truncated Bidmediated mitochondrion-dependent pathway triggered by Fas signaling (28) . Since Tregs have higher susceptibility to apoptosis, especially to the stimuli including IL-2 withdrawal-induced apoptosis (29) (30) and FasL-mediated apoptosis (31), our results suggest the importance ofTCTP in inhibition of both Treg apoptosis pathways. This and other data show that CD28 co-stimulation plays a critical role for Treg survival via upregulation of survival molecules TCTP, BcI-xL and Treg transcription factor FOXP3 (32) . We therefore propose a new model of "two phase survival" for Tregs ( Fig. 7) : In the first phase, CD28-promoted survival signal plays a dominant role for FOXP3+Tregs to "escape" the negative selection of thymocytes; even TCRs on Tregs have high affinity for self-peptide/MHC complex expressed at thymic epithelial cells (33) . Several reports from this and other labs support this part of the model. CD28 co-stimulation is essential for Tregs generation, since CD28-/-deficient mice have only 20% of Tregs in comparison to that in wild-type mice (2) . CD28 costimulation significantly promotes T cell survival by upregulating numerous anti-apoptotic proteins, BcI-xL(34), Bcl-xy(lO), and TCTP (5), suggesting that promotion of Treg generation by CD28 is fulfilled by enhancing upregulation of anti-apoptotic proteins and Treg escape from thymic negative selection. TCTP transgene increased CD4+CD25+FOXP3+ thymocytes, which further consolidates this model. Whether IL-2 signaled survival plays an essential role for thymic development of Tregs is a debatable issue (22, 35) . In the second phase, IL-2/IL-2R signal plays a decisive role in Treg survival in the periphery. These and other results support the second phase model. Tregs are anergic and poor IL-2 producers (15) . In addition, CD28 signaling is not functional in promoting IL-2 and TCTP transcription and Tregs survival. In contrast, Tregs are dependent on paracrine IL-2 for survival (22) . TCTP transgene significantly contributes to IL-2-mediated Tregs survival pathway in peripheral. Taken together, the importance ofTCTP in both phases ofTreg survival revealed in this study further suggest the potential of the pathway to be targeted for therapy.
